CLEC10A and colorectal carcinoma: Whereas no differences in survival rates between low and high MGL binders were observed in the stage II patient population, clear differences were apparent when only stage III patients were considered, with a CRC-specific 10-year survival (CSS) rate of 89.3% for low MGL-binders versus 54.6% for high MGL-binders (p = 0.02, Table 1).